In the BioHarmony Drug Report Database
Eltrombopag olamine
Promacta, Revolade (eltrombopag olamine) is a small molecule pharmaceutical. Eltrombopag olamine was first approved as Promacta on 2008-11-20. It is used to treat aplastic anemia and thrombocytopenic purpura idiopathic in the USA. It has been approved in Europe to treat thrombocytopenic purpura idiopathic. Promacta’s patents are valid until 2027-08-01 (FDA).
Trade Name
|
Revolade |
|---|---|
Common Name
|
eltrombopag olamine |
ChEMBL ID
|
CHEMBL461806 |
Indication
|
aplastic anemia, thrombocytopenic purpura idiopathic |
Drug Class
|
Image (chem structure or protein)